Therapeutic effect improvement by new boron neutron capture therapy with amino acid - BSH

硼中子俘获疗法（BNCT）是基于低能量热中子照射非放射性硼-10以产生细胞内α -粒子时发生的核俘获和裂变反应。与正常细胞相比，肿瘤细胞中的l -氨基酸转运系统增强。我们设计、合成并测试了携带非天然氨基酸的硼ACBC-BSH作为BNCT的硼药。ACBC-BSH组与BPA组疗效相近。原因是我们认为ACBC-BSH的细胞外积累表明看似高的肿瘤硼浓度并不能代表真正的肿瘤细胞摄取。在双酚a中同时使用ACBC-BSH不竞争疗效，并接受有意义的生存时间。细胞水平药物分布的差异被认为是原因。本研究提示ACBC-BSH成为增效药物的可能性。

Boron neutron capture therapy (BNCT) is based on the nuclear capture and fission reactions that occur when non-radioactive Boron-10 is irradiated with low energy thermal neutrons to produce alpha- particles inside one cell level. The L-amino acid transport system in tumor cells is enhanced compared with normal cells. We designed, synthesized and tested boron carrying unnatural amino-acid, ACBC-BSH, as boron drug for BNCT. Curative effect of ACBC-BSH groups was approximately equal to BPA. The reason is that we think that extracellular accumulations of ACBC-BSH indicating that the seemingly high tumor boron concentrations did not represent the true tumor cellular uptake. And we did not compete for the curative effect by using ACBC-BSH together in BPA and accepted meaningful duration of survival time. Difference in drug distribution at the cell level was regarded as the cause. This study suggested the possibility that ACBC-BSH became the drug to add curative effect to.